Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bill Gates backs $30 million push for early Alzheimer’s diagnostics

Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

Zogenix’s seizure drug clears late-stage trial

Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.

Read More »

AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.

Read More »

Israeli firm gets U.S. nod for advanced trials for non-opiate painkiller

PainReform received FDA clearance to begin late-stage studies for a pain-relief drug that is a departure from opiate-based narcotics.

Read More »

Celgene and Acceleron’s Luspatercept Hits Primary Endpoints in Beta-Thalassemia Trial

Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.

Read More »

CTI BioPharma’s cancer drug fails late-stage trial, shares tumble

CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.

Read More »

Biogen, Eisai’s AD succeeds in mid-stage study

Japanese drugmaker Eisai Co. and Biogen Inc. said the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.

Read More »

Sanofi beefing up diabetes pipeline, sees growth returning

Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.

Read More »

Lilly’s Taltz Hits Endpoints in AS Study

Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom